BNP Paribas Financial Markets Grows Holdings in Bruker Corporation $BRKR

BNP Paribas Financial Markets raised its position in Bruker Corporation (NASDAQ:BRKR) by 61.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 842,076 shares of the medical research company’s stock after purchasing an additional 319,726 shares during the period. BNP Paribas Financial Markets’ holdings in Bruker were worth $39,670,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Covestor Ltd lifted its holdings in shares of Bruker by 304.6% during the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,066 shares during the period. CWM LLC lifted its holdings in shares of Bruker by 49.8% during the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after acquiring an additional 542 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of Bruker by 79.7% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock worth $86,000 after acquiring an additional 1,230 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 51.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after acquiring an additional 942 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. TD Cowen increased their price objective on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. Citigroup increased their price objective on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Weiss Ratings lowered shares of Bruker from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Jefferies Financial Group set a $50.00 price objective on shares of Bruker in a report on Thursday, February 12th. Finally, UBS Group increased their price objective on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Bruker presently has a consensus rating of “Hold” and an average price target of $50.54.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 27.20% of the company’s stock.

Bruker Trading Up 9.4%

NASDAQ BRKR opened at $62.70 on Thursday. Bruker Corporation has a one year low of $28.53 and a one year high of $63.02. The company’s 50 day moving average price is $41.68 and its 200 day moving average price is $43.23. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The firm has a market capitalization of $9.54 billion, a price-to-earnings ratio of -261.25, a PEG ratio of 3.43 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same quarter last year, the firm posted $0.47 earnings per share. Bruker’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.